Please use this identifier to cite or link to this item:
https://doi.org/10.1016/j.neulet.2005.04.103
DC Field | Value | |
---|---|---|
dc.title | The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson's disease patients | |
dc.contributor.author | Tan E.K. | |
dc.contributor.author | Shen H. | |
dc.contributor.author | Tan L.C.S. | |
dc.contributor.author | Farrer M. | |
dc.contributor.author | Yew K. | |
dc.contributor.author | Chua E. | |
dc.contributor.author | Jamora R.D. | |
dc.contributor.author | Puvan K. | |
dc.contributor.author | Puong K.Y. | |
dc.contributor.author | Zhao Y. | |
dc.contributor.author | Pavanni R. | |
dc.contributor.author | Wong M.C. | |
dc.contributor.author | Yih Y. | |
dc.contributor.author | Skipper L. | |
dc.contributor.author | Liu J.-J. | |
dc.date.accessioned | 2018-12-27T06:32:49Z | |
dc.date.available | 2018-12-27T06:32:49Z | |
dc.date.issued | 2005 | |
dc.identifier.citation | Tan E.K., Shen H., Tan L.C.S., Farrer M., Yew K., Chua E., Jamora R.D., Puvan K., Puong K.Y., Zhao Y., Pavanni R., Wong M.C., Yih Y., Skipper L., Liu J.-J. (2005). The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson's disease patients. Neuroscience Letters 384 (3) : 327-329. ScholarBank@NUS Repository. https://doi.org/10.1016/j.neulet.2005.04.103 | |
dc.identifier.issn | 03043940 | |
dc.identifier.uri | http://scholarbank.nus.edu.sg/handle/10635/150233 | |
dc.description.abstract | A common heterozygous leucine-rich repeat kinase 2 (LRRK2) mutation 6055G > A transition (G2019S) accounts for about 3-7% of familial Parkinson's disease (PD) and 1-1.6% sporadic PD in a number of European populations. To determine the prevalence of the G1019S mutation in our Asian population, we conducted genetic analysis of this mutation in 1000 PD and healthy controls. The G2019S mutation was not detected in any of our study subjects. The prevalence of G2019S mutation is rare (<0.1%) in our population, suggesting that occurrence of this mutation may vary amongst different ethnic races. This has important clinical implication when implementing guidelines for genetic testing. 2005 Elsevier Ireland Ltd. All rights reserved. | |
dc.publisher | Elsevier | |
dc.source | Scopus | |
dc.subject | LRRK2 | |
dc.subject | Mutation | |
dc.subject | Parkinson's disease | |
dc.type | Article | |
dc.contributor.department | PHARMACOLOGY | |
dc.contributor.department | DUKE-NUS MEDICAL SCHOOL | |
dc.description.doi | 10.1016/j.neulet.2005.04.103 | |
dc.description.sourcetitle | Neuroscience Letters | |
dc.description.volume | 384 | |
dc.description.issue | 3 | |
dc.description.page | 327-329 | |
dc.grant.id | NMRC | |
dc.grant.fundingagency | National Medical Research Council | |
Appears in Collections: | Staff Publications |
Show simple item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.